These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3560789)

  • 1. Excessive myocardial calcinosis in a chronic hemodialyzed patient.
    Zazgornik J; Balcke P; Rokitansky A; Schmidt P; Kopsa H; Minar E; Graninger W
    Klin Wochenschr; 1987 Jan; 65(2):97-100. PubMed ID: 3560789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial calcinosis associated with hemodialysis.
    Zazgornik J; Balcke P; Biesenbach G; Kaiser W; Stockenhuber F
    Am J Cardiol; 1987 Aug; 60(4):421-2. PubMed ID: 3618514
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal replacement therapy and secondary hyperoxalemia in chronic renal failure.
    Mydlík M; Derzsiová K
    Kidney Int Suppl; 2001 Feb; 78():S304-7. PubMed ID: 11169031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary hyperoxalemia in chronic renal failure.
    Balcke P; Schmidt P; Zazgornik J; Kopsa H; Deutsch E
    Int J Artif Organs; 1982 May; 5(3):141-3. PubMed ID: 7107047
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients.
    Ono K
    Clin Nephrol; 1986 Nov; 26(5):239-43. PubMed ID: 3802587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major factors modulating the serum oxalic acid level in hemodialysis patients.
    Ogawa Y; Machida N; Jahana M; Gakiya M; Chinen Y; Oda M; Morozumi M; Sugaya K
    Front Biosci; 2004 Sep; 9():2901-8. PubMed ID: 15353324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary hyperparathyroidism in patients on long-term hemodialysis].
    Janda J
    Zentralbl Allg Pathol; 1986; 132(5-6):523-31. PubMed ID: 3564736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary hyperparathyroidism in chronic renal failure. The clinical spectrum in uremia, during hemodialysis, and after renal transplantation.
    Massry SG; Coburn JW; Popovtzer MM; Shinaberger JH; Maxwell MH; Kleeman CR
    Arch Intern Med; 1969 Oct; 124(4):431-41. PubMed ID: 4901739
    [No Abstract]   [Full Text] [Related]  

  • 11. [Secondary hyperparathyroidism in the course of uremia].
    Matusik J
    Patol Pol; 1973; 24(2):333-8. PubMed ID: 4726774
    [No Abstract]   [Full Text] [Related]  

  • 12. [Oxalic acid metabolism in chronic renal failure].
    Balcke P
    Wien Klin Wochenschr Suppl; 1985; 160():1-15. PubMed ID: 3859955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ascorbic acid aggravates secondary hyperoxalemia in patients on chronic hemodialysis.
    Balcke P; Schmidt P; Zazgornik J; Kopsa H; Haubenstock A
    Ann Intern Med; 1984 Sep; 101(3):344-5. PubMed ID: 6465702
    [No Abstract]   [Full Text] [Related]  

  • 14. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
    Cozzolino M; Dusso AS; Liapis H; Finch J; Lu Y; Burke SK; Slatopolsky E
    J Am Soc Nephrol; 2002 Sep; 13(9):2299-308. PubMed ID: 12191974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxalic Acid as a uremic toxin.
    Mydlík M; Derzsiová K
    J Ren Nutr; 2008 Jan; 18(1):33-9. PubMed ID: 18089441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary oxalosis: a cause of delayed recovery of renal function in the setting of acute renal failure.
    Alkhunaizi AM; Chan L
    J Am Soc Nephrol; 1996 Nov; 7(11):2320-6. PubMed ID: 8959621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal.
    Costello JF; Sadovnic MJ; Cottington EM
    J Am Soc Nephrol; 1991 Jun; 1(12):1289-98. PubMed ID: 1912391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echocardiographic features in a patient with primary oxalosis.
    Yoshioka J; Park YD; Tanaka Y; Kobayashi Y; Miyajima M; Tani A; Hori M; Shirai D
    Echocardiography; 2001 Oct; 18(7):599-602. PubMed ID: 11737970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone changes in end-stage oxalosis.
    Brancaccio D; Poggi A; Ciccarelli C; Bellini F; Galmozzi C; Poletti I; Maggiore Q
    AJR Am J Roentgenol; 1981 May; 136(5):935-9. PubMed ID: 6784531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal oxalosis. A clinicopathologic report.
    Wells CG; Johnson RJ; Qingli L; Bunt-Milam AH; Kalina RE
    Arch Ophthalmol; 1989 Nov; 107(11):1638-43. PubMed ID: 2818286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.